Drugs / BTD-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03150498 | May → Jul 2017 | — | Balance Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03107013 | Apr → May 2017 | — | Balance Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02512588 | Sep 2015 → Feb 2018 | idiopathic hypersomnia, narcolepsy without cataplexy | Balance Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02512588 ↗ |
| Route | Oral | “Study of Oral BTD-001” NCT02512588 ↗ |